Clinical Studies
A clinical program spanning imaging, prognosis, diagnosis and the first human delivery and dosimetry study supporting therapeutic development.
64Cu-DOTA-AE105 | Phase 1
GBM delivery and dosimetry
Ongoing Phase 1 study within the uTREAT® glioblastoma program evaluating regional delivery, biodistribution and dosimetry of 64Cu-DOTA-AE105 at imaging and dosimetry activity using super-selective intra-arterial cerebral administration (SIACI). The delivery mode is an important part of the investigation in this trial due to delivery of high concentration to the tumor.
uTRACE® | Phase 2
Prostate cancer
Clinical program evaluating uPAR PET for non-invasive characterization of prostate cancer aggressiveness for patients in active surveillance. The prostate cancer indication is licensed to Curium. The program builds on earlier prospective phase 2 trial evidence showing a significant relationship between uPAR PET uptake and Gleason score.
uTRACE®
Other tumor types
Clinical studies have evaluated uPAR PET in glioma, head and neck cancer, neuroendocrine neoplasms, breast cancer, non-small cell lung cancer and bladder cancer. Study objectives vary and include target visualization, prognostic value and risk stratification.
